Insider filing · BCDA

Andrew Scott Blank bought $251K of BioCardia (BCDA)

Executed Apr 23 2025, disclosed Apr 25 2025, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Apr 25 2025), the stock returned +6.5% (delay-adjusted); from the execution session (Apr 23 2025), +4.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

AB Andrew Scott Blank Director profile →

Andrew Scott Blank (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in BCDA. Across 1 priced purchase filing, the average 21-session return was +20.8% from execution and +27.4% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 4 days.

BCDA BCDA BCDA · 6 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→